Exenatide is a glucagon-like peptide-1 agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
The agreement calls for Axsome to issue Hetero a license to sell its generic version on or after Sept. 1, 2040, if Sunosi is granted pediatric exclusivity.
